2023

Lang, N. , Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B. , Lees, J. , Petrie, M. and Lang, N. (2023) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, (Accepted for Publication)

Cohen, A. T. et al. (2023) A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK. Current Medical Research and Opinion, 39(3), pp. 483-495. (doi: 10.1080/03007995.2023.2167441) (PMID:36629478)

2022

Stewart, G. D. et al. (2022) A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). British Journal of Cancer, 127(6), pp. 1051-1060. (doi: 10.1038/s41416-022-01883-7) (PMID:35739300) (PMCID:PMC9470559)

Tomita, Y. et al. (2022) Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO Open, 7(5), 100564. (doi: 10.1016/j.esmoop.2022.100564) (PMID:36037566) (PMCID:PMC9588905)

Powles, T. et al. (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 23(9), pp. 1133-1144. (doi: 10.1016/S1470-2045(22)00487-9) (PMID:36055304)

Venugopal, B., Pillai, M., Powles, T., Savage, P., Michael, A., Fife, K., Klair, B., Perrot, V. and Szabados, B. (2022) Early clinical experience with cabozantinib for advanced renal cell carcinoma in the UK: real-world treatment pathways and clinical outcomes. Clinical Genitourinary Cancer, 20(1), 94-94.e10. (doi: 10.1016/j.clgc.2021.09.005) (PMID:34802966)

2021

Ursprung, S. et al. (2021) The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol. BMC Cancer, 21(1), 1238. (doi: 10.1186/s12885-021-08965-4) (PMCID:PMC8600815)

Choueiri, T. K. et al. (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. New England Journal of Medicine, 385(8), pp. 683-694. (doi: 10.1056/NEJMoa2106391) (PMID:34407342)

Derby, S. , Wallace, J., Venugopal, B. and Garcia, A. C. (2021) Advanced penile cancer presenting with renal failure. Oncology, 35(7), pp. 425-428. (doi: 10.46883/onc.2021.3507.0425) (PMID:34264567)

Choueiri, T. K. et al. (2021) Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open, 6(3), 100101. (doi: 10.1016/j.esmoop.2021.100101) (PMID:33901870) (PMCID:PMC8099757)

2020

Choueiri, T. K. et al. (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of Oncology, 31(8), pp. 1030-1039. (doi: 10.1016/j.annonc.2020.04.010) (PMID:32339648) (PMCID:PMC8436592)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

2019

Motzer, R. J. et al. (2019) Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 380(12), pp. 1103-1115. (doi: 10.1056/NEJMoa1816047) (PMID:30779531) (PMCID:PMC6716603)

2018

Cook, N. et al. (2018) A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 118(6), pp. 793-801. (doi: 10.1038/bjc.2017.495) (PMID:29438372) (PMCID:PMC5877439)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi: 10.1111/bju.14025) (PMID:28940952)

2015

Venugopal, B., Awada, A., Evans, T.R.J. , Dueland, S., Hendlisz, A., Rasch, W., Hernes, K., Hagen, S. and Aamdal, S. (2015) A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 76(4), pp. 785-792. (doi: 10.1007/s00280-015-2846-0) (PMID:26289594)

2013

Venugopal, B. et al. (2013) A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clinical Cancer Research, 19(15), pp. 4262-4272. (doi: 10.1158/1078-0432.CCR-13-0312)

Venugopal, B., Ansari, J., Aitchison, M., Tho, L., Campbell, R. and Jones, R.J. (2013) Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urology, 13(26), (doi: 10.1186/1471-2490-13-26)

2012

O’Bryant, C.L. et al. (2012) An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemotherapy and Pharmacology, 69(3), pp. 605-612. (doi: 10.1007/s00280-011-1733-6)

2011

Venugopal, B. and Evans, T.R.J. (2011) Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics. Current Medicinal Chemistry, 18(11), pp. 1658-1671.

Venugopal, B. and Evans, T.R.J. (2011) Gemcitabine elaidate cytotoxic agent oncolytic. Drugs of the Future, 36(6), pp. 427-432.

2010

Brown, S. D., Nativo, P., Smith, J. A., Stirling, D., Edwards, P. R., Venugopal, B., Flint, D. J., Plumb, J.A., Graham, D. and Wheate, N. J. (2010) Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin. Journal of the American Chemical Society, 132(13), pp. 4678-4684. (doi: 10.1021/ja908117a)

2009

Venugopal, B. and Evans, T.R.J. (2009) Coexistent malignant melanoma and renal cell carcinoma. Tumori, 95(4), pp. 518-520.

Articles

Lang, N. , Rankin, S., Elyan, B., Jones, R., Venugopal, B., Mark, P. B. , Lees, J. , Petrie, M. and Lang, N. (2023) Cardiovascular eligibility criteria and adverse event reporting in combined immune checkpoint and VEGF inhibitors trials. JACC: CardioOncology, (Accepted for Publication)

Cohen, A. T. et al. (2023) A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK. Current Medical Research and Opinion, 39(3), pp. 483-495. (doi: 10.1080/03007995.2023.2167441) (PMID:36629478)

Stewart, G. D. et al. (2022) A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). British Journal of Cancer, 127(6), pp. 1051-1060. (doi: 10.1038/s41416-022-01883-7) (PMID:35739300) (PMCID:PMC9470559)

Tomita, Y. et al. (2022) Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101. ESMO Open, 7(5), 100564. (doi: 10.1016/j.esmoop.2022.100564) (PMID:36037566) (PMCID:PMC9588905)

Powles, T. et al. (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 23(9), pp. 1133-1144. (doi: 10.1016/S1470-2045(22)00487-9) (PMID:36055304)

Venugopal, B., Pillai, M., Powles, T., Savage, P., Michael, A., Fife, K., Klair, B., Perrot, V. and Szabados, B. (2022) Early clinical experience with cabozantinib for advanced renal cell carcinoma in the UK: real-world treatment pathways and clinical outcomes. Clinical Genitourinary Cancer, 20(1), 94-94.e10. (doi: 10.1016/j.clgc.2021.09.005) (PMID:34802966)

Ursprung, S. et al. (2021) The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol. BMC Cancer, 21(1), 1238. (doi: 10.1186/s12885-021-08965-4) (PMCID:PMC8600815)

Choueiri, T. K. et al. (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. New England Journal of Medicine, 385(8), pp. 683-694. (doi: 10.1056/NEJMoa2106391) (PMID:34407342)

Derby, S. , Wallace, J., Venugopal, B. and Garcia, A. C. (2021) Advanced penile cancer presenting with renal failure. Oncology, 35(7), pp. 425-428. (doi: 10.46883/onc.2021.3507.0425) (PMID:34264567)

Choueiri, T. K. et al. (2021) Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open, 6(3), 100101. (doi: 10.1016/j.esmoop.2021.100101) (PMID:33901870) (PMCID:PMC8099757)

Choueiri, T. K. et al. (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Annals of Oncology, 31(8), pp. 1030-1039. (doi: 10.1016/j.annonc.2020.04.010) (PMID:32339648) (PMCID:PMC8436592)

Dobbin, S. J.H. et al. (2020) Cardiotoxicity and myocardial hypoperfusion associated with anti-VEGF therapies: prospective cardiac magnetic resonance imaging in patients with cancer. European Journal of Heart Failure, 22(7), pp. 1276-1277. (doi: 10.1002/ejhf.1847) (PMID:32379945)

Motzer, R. J. et al. (2019) Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 380(12), pp. 1103-1115. (doi: 10.1056/NEJMoa1816047) (PMID:30779531) (PMCID:PMC6716603)

Cook, N. et al. (2018) A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 118(6), pp. 793-801. (doi: 10.1038/bjc.2017.495) (PMID:29438372) (PMCID:PMC5877439)

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi: 10.1111/bju.14025) (PMID:28940952)

Venugopal, B., Awada, A., Evans, T.R.J. , Dueland, S., Hendlisz, A., Rasch, W., Hernes, K., Hagen, S. and Aamdal, S. (2015) A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 76(4), pp. 785-792. (doi: 10.1007/s00280-015-2846-0) (PMID:26289594)

Venugopal, B. et al. (2013) A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clinical Cancer Research, 19(15), pp. 4262-4272. (doi: 10.1158/1078-0432.CCR-13-0312)

Venugopal, B., Ansari, J., Aitchison, M., Tho, L., Campbell, R. and Jones, R.J. (2013) Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma. BMC Urology, 13(26), (doi: 10.1186/1471-2490-13-26)

O’Bryant, C.L. et al. (2012) An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemotherapy and Pharmacology, 69(3), pp. 605-612. (doi: 10.1007/s00280-011-1733-6)

Venugopal, B. and Evans, T.R.J. (2011) Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics. Current Medicinal Chemistry, 18(11), pp. 1658-1671.

Venugopal, B. and Evans, T.R.J. (2011) Gemcitabine elaidate cytotoxic agent oncolytic. Drugs of the Future, 36(6), pp. 427-432.

Brown, S. D., Nativo, P., Smith, J. A., Stirling, D., Edwards, P. R., Venugopal, B., Flint, D. J., Plumb, J.A., Graham, D. and Wheate, N. J. (2010) Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin. Journal of the American Chemical Society, 132(13), pp. 4678-4684. (doi: 10.1021/ja908117a)

Venugopal, B. and Evans, T.R.J. (2009) Coexistent malignant melanoma and renal cell carcinoma. Tumori, 95(4), pp. 518-520.